Intracellular Delivery III

Market Entry Barriers of Nanomedicines

  • Aleš Prokop
  • Volkmar Weissig

Part of the Fundamental Biomedical Technologies book series (FBMT)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Introductory Chapters

    1. Front Matter
      Pages 1-1
  3. EPR Effect and ECM Modification

  4. How to Extend the Circulation Time of Nanovehicles

  5. Differences Between In Vivo Status in Men and Mice

    1. Front Matter
      Pages 147-147
  6. Cell-Specific Targeting

    1. Front Matter
      Pages 161-161
    2. Roy van der Meel, Laurens J. C. Vehmeijer, Robbert Jan Kok, Gert Storm, Ethlinn V. B. van Gaal
      Pages 163-200
    3. Ru Wen, Afoma C. Umeano, Shanta Dhar
      Pages 229-254
    4. Amit Singh, Thanh-Huyen Tran, Mansoor M. Amiji
      Pages 255-269
  7. Improved Imaging

    1. Front Matter
      Pages 271-271
    2. Nicolas Anton, François Hallouard, Mohamed F. Attia, Thierry F. Vandamme
      Pages 273-300
    3. Yasuhiro Matsumura, Masahiro Yasunaga
      Pages 323-337
  8. Quantitative PK Treatment, Systems Biology and Drug Discovery

    1. Front Matter
      Pages 339-339
    2. Amit Ranjan Maity, David Stepensky
      Pages 341-362
    3. Lars Kuepfer, Christoph Niederalt, Thomas Wendl, Jan-Frederik Schlender, Michael Block, Thomas Eissing et al.
      Pages 363-374
    4. Yi Wen Kong, Erik C. Dreaden, Paula T. Hammond, Michael B. Yaffe
      Pages 375-402
  9. Market Situation and Commercialization of Nanotechnology

    1. Front Matter
      Pages 403-403
  10. Back Matter
    Pages 451-453

About this book


A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new “drugs” will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently “nanomaterials” have been said to “show promise” but none of these promises have so far been “reduced” to human clinical practice.

The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies.

Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug–carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile.


Biochemical targeting Cellular (tissue) targeting Computational means of target discovery Discovery applicable for the Pharmaceutical industry Discovery of targeting

Editors and affiliations

  • Aleš Prokop
    • 1
  • Volkmar Weissig
    • 2
  1. 1.Biomolecular and Chemical EngineeringVanderbilt University Biomolecular and Chemical EngineeringNashvilleUSA
  2. 2.Pharmaceutical SciencesMidwestern University Pharmaceutical SciencesGLENDALEUSA

Bibliographic information